MATEON THERAPEUTICS, INC. (OTCMKTS:MATN) Files An 8-K Submission of Matters to a Vote of Security Holders
Item5.07
|
Submission of Matters to a Vote of Security Holders. |
(a) On June9, 2017, Mateon Therapeutics, Inc. (the Company) held
its 2017 Annual Meeting of the stockholders of the Company (the
Annual Meeting) at the offices of Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C., 44 Montgomery Street, 36th Floor, San
Francisco, California 94104.
(b) Of the 26,544,934 shares of the Companys common stock
entitled to vote at the Annual Meeting, 16,750,769 shares were
represented at the meeting in person or by proxy, constituting a
quorum. The voting results for each proposal considered at the
Annual Meeting are presented below, and each proposal is
described in further detail below and in the Companys definitive
proxy statement filed with the Securities and Exchange Commission
on April26, 2017 (the Proxy Statement).
1. The Companys stockholders elected the five individuals listed
below as members of the Companys Board of Directors to hold
office until the 2018 annual meeting of stockholders and until
their successors are duly elected and qualified.
|
Name |
VotesFor | VotesWithheld | BrokerNon- Votes | |||||||||
|
David J. Chaplin, Ph.D. |
3,686,654 | 3,042,222 | 10,021,893 | |||||||||
|
Donald R. Reynolds |
3,919,572 | 2,809,304 | 10,021,893 | |||||||||
|
Bobby W. Sandage Jr., Ph.D. |
3,578,948 | 3,149,928 | 10,021,893 | |||||||||
|
Simon C. Pedder, Ph.D. |
3,585,921 | 3,142,955 | 10,021,893 | |||||||||
|
William D. Schwieterman, M.D. |
3,507,988 | 3,220,888 | 10,021,893 |
2. The stockholders approved and ratified the appointment of OUM
Co. LLP as the Companys independent registered public accounting
firm for the fiscal year ending December31, 2017.
| VotesFor | VotesAgainst | VotesAbstained | BrokerNon-Votes | |||
| 12,449,495 | 3,281,817 | 1,019,457 |
About MATEON THERAPEUTICS, INC. (OTCMKTS:MATN)
Mateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor’s blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.
